Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval
In Urothelial Carcinoma
The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.
